Home›Trial›NCT07421739
NCT07421739RECRUITING

Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects

Study Summary

To assess subject-centric real-world evidence of QoL outcomes in subjects enrolled in the global Phase 3 AU-011-301 clinical trial.

Conditions
Choroidal MelanomaIndeterminate LesionsUveal MelanomaOcular Melanoma
Interventions / Drugs
Non-interventional, digital, patient-reported, real-world study
View on ClinicalTrials.gov ↗
Sponsor
AURA
Aura Biosciences
Ocular Oncology
C56/100
Study Details
Enrollment15 participants
Primary Completion—
Lead SponsorAura Biosciences
Data Retrieved2026-04-11 02:55:09.188953+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 15 participants
Sponsor Catalyst Profile

Aura Biosciences (AURA) is the sponsoring company for this trial. BiotechSign currently grades this company C (56/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

AURA Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.